06.11.2012 - Ziarco has raised €21.1m in a series A financing round. The start-up from four former Pfizer colleagues gets the money from their former employer.
Ziarco Pharma Ltd. from Canterbury secured €21.1m (GBP16.8m) in a series A financing round. Investors are US venture fund Biotechnology Value Fund L.P. and other affiliates of BVF Partners L.P. (“BVF”) as well as Pfizer Venture Investments (“PVI”). Ziarco is a new clinical-stage biotechnology company founded by President and CEO Mike Yeadon, a former Vice President and Chief Scientific Officer of Pfizer’s Allergy and Respiratory Research Unit in Sandwich. Together with three former Pfizer colleagues, he directs the start-up which aims to develop innovative therapeutics targeting inflammatory and allergic diseases. One of the peers, CSO Steve Liu, claims that the most advanced clinical programme, ZPL-3893787 – a histamine H4 receptor (H4R) antagonist – could potentially be used to treat several major diseases, including asthma, allergic rhinitis, pain and a variety of inflammatory skin conditions. This programme is included in a deal made by Ziarco and Pfizer Inc. that promises the start-up exclusive worldwide rights to commercialise a range of clinical, preclinical and research assets. In return, Pfizer will receive equity as well as certain product-based milestone and royalty payments.
The lead compound of the H4R antagonist programme has completed a Phase I multiple ascending dose study. Other programmes in various stages of development include a clinical stage cytosolic phosholipase A2 (cPLA2) inhibitor, histamine H3 receptor antagonists possessing CNS-sparing properties as well as early-stage spleen tyrosine kinase (SYK) inhibitor molecules suitable for topical administration.
20.01.2015 Ebola research projects are set to receive €215m in funding from the European Commission’s IMI2 Ebola+ programme. Among the project partners are vaccine developers Glaxosmithkline, Johnson&Johnson and Merck.
13.01.2015 Shire beefs up its rare disease portfolio after acquiring NPS Pharma with the aim of becoming a leading biotech in a US$5.2bn deal. Part of the deal is the US biotech's lead portfolio of gastrointestinal and hormone replacement therapies.
09.01.2015 The excitement surrounding CRISPR genome editing shows no sign of abating. This month, Novartis and US biotech Intellia Therapeutics became the first ever biotech-pharma collaboration to use the groundbreaking technology.
06.01.2015 With the aim to utilise Ireland’s many natural resources and keep abreast of the latest EU developments in bioeconomy, a multi-disciplinary team has been funded to maximise national income, exports and job creation related to Ireland’s bioeconomy.